![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 7
Zeitschriftenartikel
Pascual, Tomas; Oliveira, Mafalda; Villagrasa, Patricia; Ortega, Vanesa; Pare, Laia; Bermejo, Begona; Morales, Serafin; Amillano, Kepa; Lopez, Rafael; Galvan, Patricia; Canes, Jordi; Salvador, Fernando; Nuciforo, Paolo; Rubio, Isabel T.; Llombart-Cussac, Antonio; Di Cosimo, Serena; Baselga, Jose; Harbeck, Nadia; Prat, Aleix und Cortes, Javier
(2021):
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial.
In: Npj Breast Cancer, Bd. 7, Nr. 1, 145
Pizzamiglio, Sara; Ciniselli, Chiara Maura; Triulzi, Tiziana; Gargiuli, Chiara; De Cecco, Loris; de Azambuja, Evandro; Fumagalli, Debora; Sotiriou, Christos; Harbeck, Nadia; Izquierdo, Miguel; Nuciforo, Paolo; Huober, Jens; Cappelletti, Vera; Cinieri, Saverio; Piccart, Martine; Daidone, Maria Grazia; Pruneri, Giancarlo; Colombo, Mario Paolo; Tagliabue, Elda; Verderio, Paolo und Di Cosimo, Serena
(2021):
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis.
In: Clinical Cancer Research, Bd. 27, Nr. 23: S. 6307-6313
Vathiotis, Ioannis A.; Moutafi, Myrto K.; Divakar, Prajan; Aung, Thazin Nwe; Qing, Tao; Fernandez, Aileen; Yaghoobi, Vesal; El-Abed, Sarra; Wang, Yingbo; Guillaume, Sebastien; Nuciforo, Paolo; Huober, Jens; Di Cosimo, Serena; Kim, Sung-Bae; Harbeck, Nadia; Gomez, Henry; Shafi, Saba; Syrigos, Konstantinos N.; Fountzilas, George; Sotiriou, Christos; Pusztai, Lajos; Warren, Sarah und Rimm, David L.
(2021):
Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer.
In: Clinical Cancer Research, Bd. 27, Nr. 22: S. 6156-6163
Venet, David; Rediti, Mattia; Maetens, Marion; Fumagalli, Debora; Brown, David N.; Majjaj, Samira; Salgado, Roberto; Pusztai, Lajos; Harbeck, Nadia; El-Abed, Sarra; Wang, Yingbo; Saura, Cristina; Gomez, Henry; Semiglazov, Vladimir Fedorovich; de Azambuja, Evandro; Huober, Jens; Nuciforo, Paolo; Di Cosimo, Serena; Piccart, Martine; Loi, Sherene; Rothe, Francoise und Sotiriou, Christos
(2021):
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
In: Clinical Cancer Research, Bd. 27, Nr. 20: S. 5607-5618
Di Cosimo, Serena; Triulzi, Tiziana; Pizzamiglio, Sara; De Cecco, Loris; de Azambuja, Evandro; Fumagalli, Debora; Putzai, Lajos; Harbeck, Nadia; Izquierdo, Miguel; de la Pena, Lorena; Daidone, Maria Grazia; Huober, Jens; Gori, Stefania; Cinieri, Saverio; Torri, Valter; Baselga, Jose; Piccart, Martine; de Braud, Filippo G.; Apolone, Giovanni; Verderio, Paolo und Tagliabue, Elda
(2019):
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.
In: European Journal of Cancer, Bd. 118: S. 1-9
Powles, Ryan L.; Redmond, David; Sotiriou, Christos; Loi, Sherene; Fumagalli, Debora; Nuciforo, Paolo; Harbeck, Nadia; Azambuja, Evandro de; Sarp, Severine; Di Cosimo, Serena; Huober, Jens; Baselga, Jose; Piccart-Gebhart, Martine; Elemento, Olivier; Pusztai, Lajos und Hatzis, Christos
(2018):
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
In: Jama Oncology, Bd. 4, Nr. 11, e181564
Ponde, Noam; Bradbury, Ian; Lambertini, Matteo; Ewer, Michael; Campbell, Christine; Ameels, Helene; Zardavas, Dimitrios; Di Cosimo, Serena; Baselga, Jose; Huober, Jens; Izquierdo, Miguel; Fumagalli, Debora; Bozovic-Spasojevic, Ivana; Maetens, Marion; Harbeck, Nadia; Pusztai, Lajos; Berghorn, Michael; Im, Young-Hyuck; Ruiz Borrego, Manuel; Chen, Dar-Ren; Rodeheffer, Richard; Piccart, Martine; Suter, Thomas und Azambuja, Evandro de
(2018):
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
In: Breast Cancer Research and Treatment, Bd. 168, Nr. 3: S. 631-638